A Phase 2 interventional study of Ensifentrine and Placebo in Pulmonary Disease, Chronic Obstructive, COPD, sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA. Active, not recruiting at 3 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 2, and was the 9th registered.
5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 62 across 3,844 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 79 across the 15 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 4 most frequent:
This study is registered under Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 15th largest by enrollment, is the only one that started in 2022, is one of 18 in phase 2, and was the 20th registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for new ways to treat chronic obstructive pulmonary disease (COPD). COPD is a long-lasting swelling of the airways that makes it hard to breathe. Researchers want to learn if a trial medicine called ensifentrine can help treat sputum caused by COPD. In this trial, researchers will compare a trial medicine called ensifentrine to a placebo. A placebo looks like the trial medicine but has no medicine in it. Using a placebo helps researchers better understand the effects of a trial medicine.
The goal of this trial is to learn about the effect of ensifentrine on a substance found in mucus (sputum) from the lungs that may be a sign of inflammation in participants with COPD.
5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
This study's enrollment of 70 is above the median of 62 across 3,844 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
First submitted before Verona Pharma plc became part of Merck & Co., Inc.
Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Nov 3, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In treatment period 1 participants will receive 3 mg ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks followed by treatment period 2 during which participants will receive placebo matching ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks. Throughout treatment sequence 1 participants will receive LABA/LAMA background therapy.
Drug: Ensifentrine · Drug: Placebo · Drug: LABA/LAMA
In treatment period 1 participants will receive placebo matching ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks followed by treatment period 2 during which participants will receive 3 mg ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks. Throughout treatment sequence 2 participants will receive LABA/LAMA background therapy.
Drug: Ensifentrine · Drug: Placebo · Drug: LABA/LAMA
Ensifentrine administered twice daily by oral inhalation via a standard jet nebulizer.
Placebo matching ensifentrine administered twice daily by oral inhalation via a standard jet nebulizer.
Background treatment of LAMA/LABA administered per product approved label delivered by oral inhalation.
Also known as: Anoro®
The Absolute Change From Baseline in Sputum Neutrophil Cell Numbers
The Absolute change from baseline in sputum neutrophil cell numbers will be reported.
Time frame: Baseline and 8 Weeks
Absolute Change in Cell Numbers From Baseline in Sputum Cell Counts
Absolute change in cell numbers from baseline in sputum cell counts (eosinophils, basophils, macrophages, lymphocytes, total cells) will be reported.
Time frame: Baseline and 8 Weeks
Percent Change From Baseline in Sputum Cell Counts
Percent change from baseline in sputum cell counts (neutrophils, eosinophils, basophils, macrophages, lymphocytes, and total cells) will be reported.
Time frame: Baseline and 8 Weeks
Percent Change From Baseline in Cytokines
Percent Change From Baseline in Cytokines will be reported.
Time frame: Baseline and 8 Weeks
Percent Change From Baseline in Proteases
Percent Change From Baseline in Proteases will be reported.
Time frame: Baseline and 8 Weeks
Percent Change From Baseline in Markers of Inflammation
Percent Change From Baseline in Markers of Inflammation will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 4 Weeks
Change from baseline in FEV1 at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in FEV1 at 8 Weeks
Change from baseline in FEV1 at 8 weeks during the treatment period (postdose) will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Forced Vital Capacity (FVC) at 4 Weeks
Change from baseline in FVC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in FVC at 8 Weeks
Change from baseline in FVC at 8 weeks during the treatment period (postdose) will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Residual Volume (RV) at 4 Weeks
Change from baseline in RV at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in RV at 8 Weeks
Change from baseline in RV at 8 weeks (postdose) during the treatment period will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Functional Residual Capacity (FRC) at 4 Weeks
Change from baseline in FRC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in FRC at 8 Weeks
Change from baseline in FRC at 8 weeks (postdose) during the treatment period will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Total Lung Capacity (TLC) at 4 Weeks
Change from baseline in TLC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in TLC at 8 Weeks
Change from baseline in TLC at 8 weeks (postdose) during the treatment period will be reported.
Time frame: Baseline and 8 Weeks
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Number of participants who experience one or more adverse events will be reported.
Time frame: Up to approximately 8 Weeks
Change From Baseline in Systolic Blood Pressure
Change from baseline in systolic blood pressure will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Diastolic Blood Pressure
Change from baseline in diastolic blood pressure will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Heart Rate
Change from baseline in heart rate will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in QRS Duration
Change from baseline in QRS duration will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)
Change from baseline in QTcF will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in QT Interval
Change from baseline for in QT interval will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Absolute Blood Cell Counts at 4 Weeks
Change from baseline in absolute blood cell counts at 4 weeks will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in Cytokines at 4 Weeks
Change From Baseline in Cytokines at 4 Weeks will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in Proteases at 4 Weeks
Change From Baseline in Proteases at 4 Weeks will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in Markers of Inflammation at 4 Weeks
Change From Baseline in Markers of Inflammation at 4 Weeks will be reported.
Time frame: Baseline and 4 Weeks
Change From Baseline in Absolute Blood Cell Counts at 8 Weeks
Change from baseline in absolute blood cell counts at 8 weeks will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Cytokines at 8 Weeks
Change from baseline in cytokines at 8 weeks will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Proteases at 8 Weeks
Change from baseline in proteases at 8 weeks will be reported.
Time frame: Baseline and 8 Weeks
Change From Baseline in Blood Markers of Inflammation at 8 Weeks
Change from baseline in blood markers of inflammation at 8 weeks will be reported.
Time frame: Baseline and 8 Weeks
Percent Change From Baseline in Sputum Acetylated Proline-Glycine-Proline (AcPGP) at 8 Weeks
Percent change from baseline in sputum Acetylated Proline-Glycine-Proline (AcPGP) at 8 weeks will be reported.
Time frame: Baseline and 8 Weeks
Percent Change From Baseline in Sputum Proline-Glycine-Proline (PGP) at 8 Weeks
Percent change from baseline in sputum PGP at 8 weeks will be reported.
Time frame: Baseline and 8 Weeks
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started May 2022 (actual). Primary completion is estimated for Mar 2027, 57 months after the start.
Of 119 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 57 months is above that.
Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2026 → Mar 2027 and completion Jun 2027 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensifentrine
Pulmonary Disease, Chronic Obstructive →
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA →